GreenGro Technologies (OTCMKTS:GRNH), renowned provider of eco-friendly green technologies for the industrial hemp and cannabis industries makes a major announcement today! It has just acquired a multi-million dollar agreement to supervise manufacturing and distribution of premium-quality-grade medical cannabis products and pharmaceutical cannabinoid medicines across the United States and Mexico.
Neurofarrms, a California-based holistic and wellness company, has awarded the agreement to GreenGro, which spans 5 years. The former is dedicated to developing transformative therapies derived from tetrahydrocannabinol (THC) and cannabinoids (CBD) for people suffering from diseases with high unmet medical needs.
Victor Rocha, Founder and CEO of Neurofarms, is hopeful of the application of their CBD-product line to over a thousand patients, with almost zero side effects. It gives them a chance to expand potential of their portfolio and address several types of medical conditions, thereby cementing their position as one of the most successful and influential players in the emerging cannabis-based segment of the industry.
James Haas, Chairman and Chief Operating Officer of GreenGro Technologies, believes the combined potential of both companies will elevate product quality and efficacy for customers like never before. Neurofarms’s specific formulations along with GreenGro’s business infrastructure are the perfect launch pad for an exciting partnership.
On Tuesday, GRNH stock ended flat at $0.0085 with more than 38.40 million shares, compared to its average volume of 3.51 million shares. The stock has moved within a range of $0.0082 – 0.0110 after opening the trade at $0.0085.